NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND

NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, led by Neil Miller, Richard Rutter, Grant Hawthorne, Rupert Sandbrink, and others, has announced the closing of its oversubscribed £50 Million Series B financing led by SV Health Investors’ Dementia Discovery Fund (DDF) with participation from British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures alongside existing investors Omega Funds and Brandon Capital. Founding investor Parkinson’s UK, via its drug development arm the Parkinson’s Virtual Biotech, remains an active and supportive investor. Laurence Barker (SV Health Investors), Emma Johnson (British Business Bank), Charlotte Kremers (M Ventures), and Florian Muellershausen (Novartis Venture Fund) will join NRG’s board of directors. Professor David Dexter, Director of Research at Parkinson’s UK, has been appointed as a special advisor on Parkinson’s.

NRG Therapeutics has raised Series B funding to advance NRG5051, a neuroprotective candidate for ALS/MND and Parkinson’s. The financing will support Phase 1b studies in Parkinson’s and enable clinical proof of concept in ALS/MND, with first-in-human trials set for early 2026.

NRG has discovered a novel regulator of the mitochondrial permeability transition pore (mPTP), enabling the development of brain-penetrant oral inhibitors. By protecting mitochondria from protein toxicity linked to Parkinson’s and ALS/MND, these inhibitors preserve neurons and target a shared pathology in neurodegenerative diseases.

Parkinson’s cases are set to double by 2050, yet no therapies exist to slow progression; current drugs only ease symptoms. ALS/MND is similarly devastating, with limited options; aside from Qalsody for rare genetic cases, most patients with sporadic disease remain untreated.